Volume 27, Issue 3 (5-2020)                   RJMS 2020, 27(3): 9-18 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Salehi S, Radgoodarzi M. Cardiac manifestations of rheumatologic diseases in children and adolescent. RJMS 2020; 27 (3) :9-18
URL: http://rjms.iums.ac.ir/article-1-5881-en.html
Assistant Professor of Pediatric Cardiology, Department of Pediatrics, Hazrat-e- Rasool General Hospital, , dr.radgudarzi@yahoo.com
Abstract:   (2026 Views)
Today, cardiac involvement is one of the major obstacles in the treatment of patients with rheumatologic diseases. Such an involvement was introduced at the beginning of 20th century, but in the last decades, newly recognized clinical entities have been introduced owing to emerging highly sensitive, non-invasive or semi-invasive cardiac imaging techniques. Cardiac involvements in patients with rheumatologic diseases are different ranging from subclinical to severe manifestations. These manifestations are heterogeneous affecting different structures (pericardium, myocardium or endocardium). Arrhythmias may be the first manifestation of sarcoidosis. An intracardiac clot may also be a manifestation of Behcet's disease, and finally, pericarditis may be a manifestation of scleroderma. In ankylosing spondylitis, cardiac disorders can cause gradual complaints such as decreased ability to function or weaken, which are misleadingly attributed to non-clinical aspects of the disease. They are presented at the time of diagnosis of rheumatologic disorder or afterward. The cardiac involvements can also be the first presentation of rheumatologic circumstances so that some patients with rheumatologic diseases may primarily visit a cardiologist when they are attacked by this disease. Cardiac involvements can cause mortality and morbidity in patients with rheumatologic diseases. Prompt recognition of cardiovascular abnormalities is necessary for timely and appropriate management. Therapies directed towards inflammatory process are crucial to reduce cardiovascular disease morbidity and mortality. They may require aggressive immunosuppressive therapy. Although aggressive treatment of primary rheumatologic diseases can reduce the mortality rate and improve them, there are no specific guidelines and recommendations for them so far.
Full-Text [PDF 770 kb]   (1114 Downloads)    
Type of Study: review article | Subject: Pediatric Cardiology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb